Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GemPharmatech CoSHSE:688046 -0.46%77 EV-to-EBITDA is 43.93 as of Sep. 21, 2026, which is 12% above its 10-year median of 39.33. GuruFocus rates SHSE:688046 with a GF Score™ of 77/100 and a GF Value™ of ¥19.65 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 430 Biotechnology companies, GemPharmatech Co ranks worse than 82.09% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, GemPharmatech Co's enterprise value is ¥14,212.6 Mil.
GemPharmatech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ¥323.6 Mil. Therefore, GemPharmatech Co's EV-to-EBITDA for today is 43.93.
The historical rank and industry rank for GemPharmatech Co's EV-to-EBITDA or its related term are showing as below:
SHSE:688046'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 16.28 Med: 39.33 Max: 75.87
Current: 43.93
During the past 8 years, the highest EV-to-EBITDA of GemPharmatech Co was 75.87. The lowest was 16.28. And the median was 39.33.
SHSE:688046's EV-to-EBITDA is ranked worse than 82.09% of 430
companies
in the Biotechnology industry
Industry Median: 13.015
vs SHSE:688046: 43.93
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
GemPharmatech Co (SHSE:688046) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
GemPharmatech Co's PE Ratio (TTM) for today is calculated as:
GemPharmatech Co's share price for today is ¥36.61.
GemPharmatech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.447.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for GemPharmatech Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688046 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, GemPharmatech Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GemPharmatech Co EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GemPharmatech Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where GemPharmatech Co's EV-to-EBITDA falls into.
GemPharmatech Co's current Enterprise Value is ¥14,212.6 Mil.
GemPharmatech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥323.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GemPharmatech Co (SHSE:688046) has a EV-to-EBITDA of 43.93 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on GemPharmatech Co. This is 12% above median its historical median of 39.33. Over the past decade, GemPharmatech Co's EV-to-EBITDA has ranged from 16.28 to 75.87. According to the industry distribution chart, GemPharmatech Co ranks #353 out of 430 companies in the Biotechnology industry, placing it in the top 82.1%.
Is GemPharmatech Co's EV-to-EBITDA too high?
GemPharmatech Co's current EV-to-EBITDA of 43.93 is 12% above median its 10-year median of 39.33. Over the past 10 years, this metric has ranged from a low of 16.28 to a high of 75.87. The Biotechnology industry median EV-to-EBITDA is 13.02. GemPharmatech Co's value of 43.93 is 237.5% above this industry median. Based on the distribution chart, GemPharmatech Co ranks #353 out of 430 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, GemPharmatech Co has a GF Score™ of 77/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GemPharmatech Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GemPharmatech Co ranks #353 out of 430 companies for EV-to-EBITDA. This places GemPharmatech Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.02. GemPharmatech Co's value of 43.93 is 237.5% above this benchmark. Historically, GemPharmatech Co's own EV-to-EBITDA has ranged from 16.28 to 75.87 over the past decade. While the company's 10-year median is 39.33 vs. the industry median of 13.02, GemPharmatech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.02, based on 430 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GemPharmatech Co's current EV-to-EBITDA of 43.93 is 237.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on GemPharmatech Co. For the Biotechnology industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GemPharmatech Co's current EV-to-EBITDA is 43.93, which is 12% above median its own 10-year median of 39.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GemPharmatech Co stock overvalued right now?
Based on GuruFocus' analysis, GemPharmatech Co (SHSE:688046) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥19.65, compared to a current price of ¥36.61 — trading 86.3% above its estimated fair value. The current EV-to-EBITDA is 43.93, which is 12% above median its 10-year median of 39.33 and 237.5% above the Biotechnology industry median of 13.02. GemPharmatech Co's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For GemPharmatech Co (SHSE:688046), the current EV-to-EBITDA is 43.93 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GemPharmatech Co (SHSE:688046) Overvalued in 2026?
Based on GuruFocus' analysis, GemPharmatech Co stock appears to be overvalued.
The current stock price of ¥36.61 is trading 86.3% above its estimated GF Value™ of ¥19.65.
GuruFocus considers GemPharmatech Co to be Significantly Overvalued.
Key valuation signals for SHSE:688046:
EV-to-EBITDA: 43.93 (12% above median its 10-year median of 39.33)
GF Value™: ¥19.65 vs. price of ¥36.61 (86.3% above fair value)
Industry Position: 237.5% above the Biotechnology median (#353 of 430)
No single metric tells the full story. See the SHSE:688046 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GemPharmatech Co Ltd is a provider of genetically engineered mouse models and services to preclinical research and development communities. The company develops mouse models with independent intellectual property rights based on technical platforms such as gene editing, stem cells, phenotypic analysis, efficacy analysis, and sterile animals, and carries out one-stop services such as model customization, customized breeding, and functional efficacy analysis.
77GF Score
Get the complete analysis for SHSE:688046
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688046 has been successfully added to your 
